Poor
Needs Revision
Patient Risk:
Moderate
Summary
The provided response does not contain FDA-label-consistent prescribing information for MOUNJARO beyond a single supported indication claim. It includes multiple compounding/pharmacy-related statements that are not addressed or supported by the supplied MOUNJARO label text, and it omits label-required administration, contraindications, and safety details relevant to safe prescribing.
Category Scores
Accurate Statements
MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Section 1 INDICATIONS AND USAGE
Unsupported Statements
A “503A” pharmacy may compound drugs when they meet applicable FDA compounding standards.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Whether a 503A pharmacy can compound tirzepatide specifically depends on the pharmacy’s regulatory compliance.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Whether a 503A pharmacy can compound tirzepatide depends on the pharmacy’s formulation(s) and sourcing.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Compounding pharmacies typically prepare individualized drug products when commercially available options are not suitable for a specific patient.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Compounded tirzepatide may differ from branded products in concentration.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Compounded tirzepatide may differ from branded products in salt form (if applicable).
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Compounded tirzepatide may differ from branded products in excipients.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Compounded tirzepatide may differ from branded products in packaging.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Dose accuracy is a safety concern with compounded injectables.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Sterility and handling during compounding and shipping are safety concerns with compounded tirzepatide.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Batch-to-batch consistency is a safety concern with compounded tirzepatide.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Product identity and purity are safety concerns with compounded tirzepatide.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Patent and exclusivity status can drive litigation and FDA scrutiny around compounded “versions” of brand-name drugs.
Not addressed in the supplied MOUNJARO prescribing information excerpts.
Contradictions
Important Omissions
Important Administration Instructions (e.g., training for presentation, self-administration restrictions for pediatric patients and visually impaired, syringe/needle instructions for vials, dosing frequency/with or without meals, subcutaneous injection site guidance, site rotation, visual inspection, and do-not-mix guidance with insulin).
Importance:
High
Contraindications (MTC/MEN 2 history; known serious hypersensitivity to tirzepatide or excipients).
Importance:
High
Warnings and precautions included in the supplied excerpts (e.g., severe gastrointestinal adverse reactions; not recommended in patients with severe gastroparesis).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response does not provide label-supported contraindications, key administration instructions, or label warnings from the supplied excerpts; it also includes multiple unsupported statements unrelated to the provided label content. This combination could lead to incomplete or non-label-consistent prescribing communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Most statements are not supported by the supplied MOUNJARO FDA label excerpts, and label-critical prescribing information (administration instructions, contraindications, and warnings) is omitted.
Suggested Improvement
Limit claims to the supplied label content and include the relevant on-label administration instructions, contraindications, and the warning/precaution points present in the provided excerpts when discussing safe prescribing.